Lepu Biopharma Co., Ltd. filed its monthly return for the period ended 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public float requirements.

The company’s authorised and issued ordinary H shares both remained at 1.80 billion, each with a par value of RMB 1.00. No new shares were issued, cancelled, or repurchased during the month, leaving treasury share holdings at zero.

Lepu Biopharma also reported that: • Total authorised/registered share capital stood unchanged at RMB 1.80 billion. • Issued share count was steady at 1.80 billion, with no movements recorded across options, warrants, convertibles, or other equity-linked instruments. • The minimum 25% public float threshold stipulated by Main Board Rule 13.32B has been met as of 31 March 2026.

The filing, submitted on 2 April 2026 by Joint Company Secretary Ms. Li Yunyi, affirms that all listing rule obligations and statutory requirements were satisfied during the reporting period.